Biomarker Insights

Biomarker Insights is a gold open-access journal from SAGE Publications that has followed the discovery, validation and clinical use of biological markers since 2006, and its 2025 Journal Impact Factor is 1.9 in the Emerging Sources Citation Index.《生物标志物洞察》是 SAGE Publications 出版的金色开放获取期刊，2006 年创刊，关注生物标志物从发现，验证到临床使用的全过程，2025 年影响因子为 1.9，收录于新兴来源引文索引。

Scope

• The remit is any measurable indicator of a biological state, whether a gene transcript, a plasma protein, a metabolite, an image texture or a digital pathology feature.收录范围覆盖一切可测量的生物学状态指标，包括基因转录本，血浆蛋白，代谢物，影像纹理与数字病理特征。

• Discovery work spans germline variants, somatic mutation profiles, expression signatures, methylation patterns and non-coding RNA, with weight given to effect size rather than to novelty alone.发现类研究涵盖胚系变异，体细胞突变谱，表达特征，甲基化模式与非编码 RNA，并看重效应量而非单纯的新颖性。

• Proteomic submissions are expected to describe the assay platform, the antibody or the mass-spectrometric method, and the limits of detection that decide whether a marker can be measured in routine practice.蛋白质组学稿件需交代检测平台，抗体或质谱方法，以及决定标志物能否进入常规实践的检出限。

• Metabolomic and lipidomic markers are considered alongside the analytical chemistry behind them, since a profile that cannot be reproduced on a second platform has little clinical value.代谢组学与脂质组学标志物连同其背后的分析化学一并考察，在第二个平台上无法复现的谱型几乎没有临床价值。

• Liquid biopsy has a standing place, covering circulating tumour DNA, circulating tumour cells, extracellular vesicles and the microRNA signatures that travel with them.液体活检占固定篇幅，涉及循环肿瘤 DNA，循环肿瘤细胞，细胞外囊泡，以及随之流动的微小 RNA 特征。

• Imaging markers enter through radiomics, quantitative magnetic resonance, PET tracers and computational reading of histological slides, provided the acquisition protocol is reported closely enough to be repeated.影像标志物经由放射组学，定量磁共振，PET 示踪剂与组织切片的计算读片进入刊物，前提是采集方案写得足以让别处重复。

• Diagnostic studies are judged on discrimination, calibration and net clinical benefit rather than on the area under the curve alone.诊断研究按区分度，校准与净临床获益衡量，不只看曲线下面积。

• Prognostic and predictive markers are treated as separate questions, one about the course of disease and the other about who will respond to a particular treatment.预后标志物与疗效预测标志物按两个问题处理，前者关乎疾病进程，后者关乎谁会从某种治疗中获益。

• Pharmacogenomic papers deal with metabolising enzyme genotypes, transporter variants, HLA alleles and the dose adjustments that follow from them.药物基因组学论文讨论代谢酶基因型，转运体变异，HLA 等位基因，以及由此推出的剂量调整。

• Pre-analytical variables receive attention, from collection tube and fasting state to storage temperature and freeze-thaw cycles, because they decide whether two studies can be compared at all.分析前变量受到重视，从采血管与空腹状态，到保存温度与冻融次数，因为它们决定两项研究能否互相比较。

• Statistical and bioinformatics methods are in scope, including multiple-testing control, penalised regression, cross-validation and external validation in an independent cohort.统计与生物信息学方法属于范围，含多重检验控制，惩罚回归，交叉验证，以及在独立队列中的外部验证。

• Cohort descriptions and biobank-based work are accepted when specimen provenance, consent terms and follow-up duration are stated plainly.队列描述与样本库研究在写明样本来源，知情同意条款与随访时长之后可以录用。

• Validation carries as much weight as discovery, and a paper has to keep analytical validation, which concerns the assay itself, apart from clinical validation, which concerns the patient.验证与发现同等重要，论文须把分析验证与临床验证分开交代，前者针对检测方法本身，后者针对患者群体。

• Early translation is covered too, through biomarker-guided trial designs, companion diagnostics and the evidence regulators ask for before a test enters clinical use.早期转化同样在列，涉及标志物指导的试验设计，伴随诊断，以及监管机构在检测进入临床之前要求的证据。

• Article types run from original research and systematic reviews to short reports on assay development, and the intended clinical use of a marker is part of what a paper has to establish.体裁从原创研究与系统综述延伸到检测方法开发的短篇报告，标志物拟用于何种临床场景，是论文必须交代的一环。

History

• The first volume appeared in 2006 under Libertas Academica Ltd. of Auckland, New Zealand, while the post-genome hunt for measurable markers was pulling papers away from established clinical journals.首卷于 2006 年由新西兰奥克兰的 Libertas Academica Ltd. 出版，后基因组时代对可测标志物的寻找正把论文从老牌临床期刊分流出去。

• The publisher worked as a born-digital operation, issuing each article as a discrete file with its own identifier instead of assembling printed issues.出版方以原生数字方式运营，把每篇论文作为独立文件配以单独编号发布，而不是去组装印刷期次。

• PubMed indexed the title from the first volume in 2006 and has carried it without a break since, which gave a young journal a visibility its circulation could not have bought.PubMed 自 2006 年首卷起收录该刊，此后未曾中断，这份年轻刊物由此获得的能见度，靠发行量是买不到的。

• Deposit in PubMed Central went further and put the full text in an open repository, so the archive survived the publisher changes that came later.全文存入 PubMed Central 更进了一步，内容进入开放仓储，后来的出版方更迭也没能切断这份存档。

• From 2016 the imprint names Thousand Oaks, California, with SAGE Publications as publisher, and the National Library of Medicine records the shift as a straight replacement rather than as a new title.自 2016 年起，出版地记为加利福尼亚州千橡市，出版方为 SAGE Publications，美国国家医学图书馆把这一变化记为承接，而非另立新刊。

• The journal's own pages moved with the imprint, from the la-press.com address of the Libertas years to the SAGE platform, where the current aims and author instructions now sit.刊物页面随标记一同迁移，从 Libertas 时期的 la-press.com 地址转到 SAGE 平台，现行的宗旨与投稿须知都在那里。

• Volume numbers have run one to a year without a break, so the 2026 volume is the twenty-first, and every article reaches the reader as soon as it is typeset.卷号每年一卷，从未断档，2026 年已是第二十一卷，每篇论文排版完成即与读者见面。

• Crossref records carry no issue numbers for recent years, which confirms continuous publication rather than a fixed quarterly or monthly cycle.近年 Crossref 记录中没有期号，可见刊物采用连续出版，并未按季度或月度固定分期。

• Output is small, with 22 articles counted for 2025, and that figure leaves the impact factor sensitive to a handful of well-cited papers.发文量不大，2025 年计 22 篇，这一规模使影响因子对少数高被引论文格外敏感。

• The 2025 Journal Citation Reports give a cited half-life of 9.1 years and 1114 citations in total, so the back catalogue is still being read a decade after publication.2025 年期刊引证报告给出 9.1 年的引用半衰期与 1114 次总被引，十年前的旧文至今仍有人引用。

• The impact factor moved from 3.4 in 2023 to 2.6 in 2024 and then to 1.9 in 2025, a downward run across the three years for which the title carries a figure.影响因子从 2023 年的 3.4 降到 2024 年的 2.6，2025 年又降至 1.9，有据可查的三年一路下行。

• The five-year figure of 3.5 sits well above the annual one, which means the older volumes collect citations faster than the newest.五年影响因子为 3.5，远高于年度值，说明较早的卷次积累引文的速度快于最新卷。

• In the 2025 reports the title sits in the Emerging Sources Citation Index, third quartile of Medicine, Research and Experimental, ranked 129 of 191.在 2025 年的报告中，该刊列于新兴来源引文索引，属医学研究与实验类目的第三四分位，在 191 份刊物中排第 129 位。

• Every article has been free at the point of reading, and the gold share recorded for 2025 is a full 100 per cent, a figure that leaves no subscription tier anywhere in the model.所有论文在阅读端免费，2025 年记录的金色开放获取比例达到 100%，整本刊没有订阅层级。

• What the ownership change did not alter is the subject, since the same mixture of molecular, imaging and statistical work that filled the Auckland volumes still fills the California ones.出版方的更迭没有改动选题，创刊初期在奥克兰组稿的分子，影像与统计研究，如今在加州依旧如此。

Editors

• Submissions arrive through the publisher's online system, where the editorial office checks scope and completeness and decides whether the file goes out for review.稿件经出版方的在线系统递交，编辑办公室先核对范围与完整性，再决定是否送外审。

• Plagiarism screening runs on every submission, and the similarity report reaches the handling editor together with the manuscript, a step the publisher lists among its standard checks.每份稿件都过查重，相似度报告与正文一并送到责任编辑手上，出版方把这道工序列为常规检查之一。

• A handling editor takes charge of each manuscript, chooses the referees and writes the decision letter, which keeps one person accountable for the outcome.每篇稿件由一位责任编辑接手，挑选审稿人并撰写决定信，结果由此有明确的负责人。

• Review is single anonymous, as the publisher records it, so referees see author names and affiliations while authors never learn who assessed the paper.评审采用单匿名，出版方登记的口径如此，审稿人看得到作者姓名与单位，作者始终不知道评审是谁。

• Review is typically finished within about eight weeks, a pace that suits the assay-development reports the journal attracts.评审通常能在八周左右完成，这一节奏适合该刊收的检测方法开发类报告。

• Ethics approval, informed consent, trial registration and a data-availability statement are all required at submission, and the publisher's checklist names each one.伦理批件，知情同意，试验注册与数据可得性声明均为投稿必备，出版方的核查清单逐项列出。

• Authors keep copyright and publish under a Creative Commons licence, and the licence deed is recorded against each article.作者保留版权，论文按知识共享许可发布，具体许可随每篇论文登记。

• Authors are asked to give units, cut-offs and the assay platform in the methods, so a reader can see how a marker was measured and on which instrument.作者须在方法部分写明单位，阈值与检测平台，读者由此看清标志物怎样测出，用的是哪台仪器。

• An effect that outruns the resolving power of the assay is the kind of problem referees are asked to catch, and the paper usually comes back for statistical reworking.效应量超出检测方法分辨能力的稿件，正是审稿人要把住的问题，这类论文通常会退回重做统计。

• Corrections, expressions of concern and retractions follow the publisher's research-integrity procedure, written to the guidance of the Committee on Publication Ethics.更正，关注声明与撤稿按出版商的科研诚信程序处理，该程序依出版伦理委员会的指南写成。

• Authors who think a decision rests on a factual error can appeal, and the publisher's appeals procedure sets out how a rejected manuscript is looked at again.作者若认为决定建立在事实错误之上可以申诉，出版方的申诉程序规定了被拒稿件如何获得重审。

• Accepted papers carry an article processing charge, and the journal is financed that way rather than by subscriptions, so the readership is not limited by library budgets.录用论文需缴文章处理费，刊物由此获得经费，不靠订阅，读者规模不受图书馆预算限制。